Lauren Black, PhD

Senior Scientific Consultant, Charles River
Washington, D.C.

Lauren holds a B.S. from Carnegie Mellon University in Molecular Biology and a doctorate in Pharmacology/Toxicology from the Virginia Commonwealth School of Medicine. She spent two years in postdoctoral research at NIH, evaluating dopaminergic drugs and GPCRs. Lauren served in both FDA, CDER and CBER for 11 years, focusing on preclinical assessment of transplant drugs, oligos, monoclonals for autoimmune disease, treatment vaccines, and cell therapies.  She was a contributing author or committee chair for a number of FDA guidances, including immunotoxicology, oligos, xenotransplantation, and human starting doses. Since 2002, she has worked at Charles River in the Scientific Advisory Services group, where she advises both internal scientists working on IND programs, and pharmaceutical firms at all stages of development.  She was recently designated Distinguished Scientist, recognizing her contributions to accelerating high risk programs and advancing translational medicine. Lauren has taught biologics drug strategy at a number of academic meetings including the American College of Drug Development, and is a full member of the Society of Toxicology.

Picking up the Pace

The Ebola outbreak has been shining a very bright light on accelerated drug development. Charles’ River’s resident FDA expert Lauren Black explains how the process works and why it’s imp Continue reading


Conserving animals through proper reduction strategies, while also protecting humans in the long run, can be a difficult balance. A strong commitment to 3Rs helps. Continue reading